Table 2. Dendritic Cell Vaccine... | American Society of Hematology

Table 2.

Dendritic Cell Vaccine Characteristics

Patient (UPN)	Time of 1st Id Vaccine^*	No. of DC Infused (×10⁶) (1st, 2nd vaccine)	DC Purity (1st, 2nd vaccine)^† (%)
1 (1172)	4	7.5, 7.5	11, 10
2 (1243)	3	2.1, 1.9	30, 50
3 (1289)	4	3.9, 2.7	10, 34
4 (1353)	3	0.5, 3.5	6, 45
5 (1397)	6	5.5, 8.6	63, 12
6 (1396)	6	8.0, 11.1	15, 35
7 (1445)	6	3.0, 2.7	10, 13
8 (1441)	6	3.0, 3.0	21, 8
9 (1457)	6	3.0, 7.5	3, 32
10 (1483)	7	10.3, 8.4	53, 43
11 (1504)	6	6.6, 6.1	27, 53
12 (1521)	6	3.7, 3.3	10, 10

Patient (UPN)	Time of 1st Id Vaccine^*	No. of DC Infused (×10⁶) (1st, 2nd vaccine)	DC Purity (1st, 2nd vaccine)^† (%)
1 (1172)	4	7.5, 7.5	11, 10
2 (1243)	3	2.1, 1.9	30, 50
3 (1289)	4	3.9, 2.7	10, 34
4 (1353)	3	0.5, 3.5	6, 45
5 (1397)	6	5.5, 8.6	63, 12
6 (1396)	6	8.0, 11.1	15, 35
7 (1445)	6	3.0, 2.7	10, 13
8 (1441)	6	3.0, 3.0	21, 8
9 (1457)	6	3.0, 7.5	3, 32
10 (1483)	7	10.3, 8.4	53, 43
11 (1504)	6	6.6, 6.1	27, 53
12 (1521)	6	3.7, 3.3	10, 10

Time from reinfusion of the PBSC to time of first Id-pulsed DC infusion in months.

Percent of infused cells that were B- and T-cell lineage marker negative and high MHC class II expressors by flow cytometry analysis.